William Blair Reaffirms “Outperform” Rating for OptimizeRx (NASDAQ:OPRX)

OptimizeRx (NASDAQ:OPRX)‘s stock had its “outperform” rating reiterated by analysts at William Blair in a research note issued on Thursday,RTT News reports.

Several other research analysts have also issued reports on OPRX. B. Riley initiated coverage on OptimizeRx in a report on Thursday, July 25th. They issued a “buy” rating and a $18.50 price target on the stock. Roth Mkm restated a “buy” rating and issued a $16.00 target price (down previously from $20.00) on shares of OptimizeRx in a report on Thursday. Stifel Nicolaus dropped their target price on OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday. Barclays dropped their target price on OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating on the stock in a report on Thursday. Finally, Royal Bank of Canada dropped their target price on OptimizeRx from $14.00 to $7.00 and set an “outperform” rating on the stock in a report on Thursday. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, OptimizeRx currently has a consensus rating of “Moderate Buy” and an average target price of $10.42.

OptimizeRx Stock Down 34.0 %

NASDAQ:OPRX traded down $2.09 on Thursday, hitting $4.06. The stock had a trading volume of 1,962,988 shares, compared to its average volume of 140,475. The business’s fifty day moving average is $6.75 and its 200 day moving average is $9.07. The company has a market cap of $74.39 million, a PE ratio of -4.06 and a beta of 1.32. The company has a quick ratio of 3.07, a current ratio of 3.07 and a debt-to-equity ratio of 0.27. OptimizeRx has a 52 week low of $3.95 and a 52 week high of $16.65.

Institutional Trading of OptimizeRx

Institutional investors and hedge funds have recently modified their holdings of the business. Summit Securities Group LLC purchased a new stake in shares of OptimizeRx during the second quarter valued at approximately $25,000. BNP Paribas Financial Markets increased its position in OptimizeRx by 189.2% in the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock worth $28,000 after buying an additional 2,414 shares during the last quarter. Quest Partners LLC increased its position in OptimizeRx by 15,965.6% in the third quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock worth $76,000 after buying an additional 9,739 shares during the last quarter. Connors Investor Services Inc. increased its position in OptimizeRx by 15.1% in the second quarter. Connors Investor Services Inc. now owns 19,107 shares of the company’s stock worth $191,000 after buying an additional 2,500 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in OptimizeRx in the second quarter worth $282,000. 76.47% of the stock is owned by hedge funds and other institutional investors.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.